Article Sidebar

pdf
Date Published: 24/11/2023
Abstract Views: 85
Views pdf: 57
DOI: https://doi.org/10.51298/vmj.v532i1.7280
Issue
Vol. 532 No. 1 (2023)
Section
Các bài báo
How to Cite
Nguyễn, T. H., Trịnh, L. H., & Nguyễn, T. T. H. (2023). THE EFFICACY OF PACLITAXEL AND CARBOPLATIN IN PATIENTS WITH TKI-RESISTANT STAGE IV NON-SMALL CELL LUNG CANCER. Vietnam Medical Journal, 532(1). https://doi.org/10.51298/vmj.v532i1.7280

THE EFFICACY OF PACLITAXEL AND CARBOPLATIN IN PATIENTS WITH TKI-RESISTANT STAGE IV NON-SMALL CELL LUNG CANCER

Thị Hồng Nguyễn1, Lê Huy Trịnh1,, Thị Thái Hòa Nguyễn2
1 HMU
2 K Hospital

Main Article Content

Abstract

Objectives: To evaluate the efficacy of paclitaxel and carboplatin in patients with TKI-resistant stage IV non-small cell lung cancer. Materials and methods: Descriptive, retrospective, longitudinal case study of 46 patients with stage IV non-small cell lung cancer who had EGFR mutation, advanced after tyrosine kinase inhibitor therapy, treatmented with Paclitaxel – Carboplatin regimen from 01/2017 to 06/2023 at Vietnam’s National Cancer Hospital. Results: The mean age was 54,7 ± 9,1 (36-76); male/female ratio was 1/1,19; non-smoking ratio was 54,3%. The overall response rate (ORR) was 43,5%, the DCR was 80,4%. The mean progression-free survival (PFS) was 5,33 ± 0,68 months, the median progression-free survival was 4,83 months. Conclusion: In patients with TKI-resistant stage IV non-small cell lung cancer, paclitaxel – carboplatin regiment is a choice with good response and control rates.

Article Details

Keywords

non-small cell lung cancer, resistant to TKIs, Paclitaxel – Carboplatin

References

Trần Văn Thuấn. Hướng Dẫn Chẩn Đoán và Điều Trị Bệnh Ung Thư Thường Gặp. Nhà xuất bản Y học; 2019.
2. Bùi Công Toàn, Hoàng Đình Chân. Bệnh Ung Thư Phổi. NXB Y học; 2008.
3. Misiakos EP, Karidis NP, Kouraklis G. Current treatment for colorectal liver metastases. World J Gastroenterol. 2011;17(36):4067-4075. doi:10.3748/wjg.v17.i36.4067
4. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012; 13 (3):239-246. doi:10.1016/S1470-2045 (11)70393-X
5. Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011;12(8):735-742. doi:10.1016/S1470-2045(11)70184-X
6. Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma | NEJM. Accessed August 27, 2022. https://www.nejm.org/doi/ 10.1056/NEJMoa0810699?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200www.ncbi.nlm.nih.gov
7. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR. New England Journal of Medicine. 2010;362(25):2380-2388. doi:10.1056/NEJMoa0909530
8. Park et al. JAMA Onc.2016.
9. Sun D, Zhu Y, Zhu J, et al. Primary resistance to first-generation EGFR-TKIs induced by MDM2 amplification in NSCLC. Molecular Medicine. 2020;26(1):66. doi:10.1186/s10020-020-00193-z
10. G M, R C, M M, et al. Carboplatin plus pemetrexed for platinum-pretreated, advanced non-small cell lung cancer: a retrospective study with pharmacogenetic evaluation. Cancer chemotherapy and pharmacology. 2011;68(6). doi:10.1007/s00280-011-1632-x